Form 4 for TELO Telomir Pharmaceuticals, Inc.
Accepted 2026-04-24 16:05:23 ET · period of report 2026-04-22 · accession 0001493152-26-018911 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 16:05 | 2026-04-22 | TELO | Aminov Erez | CEO, COB, Dir | J - Other | $1.37 | +7.32M | 7.32M | New | +$10.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-22 | J | A | 7,319,710 | $1.37 | 7,319,710 | D | — | — | (F1) The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. (F1) The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. (F1) The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI. |